MRNA Moderna | $35.89
+5.4% | 1/16/2025 | Target Lowered by | Leerink Partners | - | Underweight -> Underweight | $31.00 -> $27.00 | Low | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 1/16/2025 |
FDMT 4D Molecular Therapeutics | $4.67
+2.0% | 1/13/2025 | Target Lowered by | Leerink Partners | Analyst Mani Foroohar | Outperform -> Outperform | $31.00 -> $27.00 | High | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 1/13/2025 |
SPRY ARS Pharmaceuticals | $13.48
+7.2% | 1/13/2025 | Target Raised by | Leerink Partners | Analyst Roanna Ruiz | Outperform -> Outperform | $26.00 -> $27.00 | High | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 1/13/2025 |
VIR Vir Biotechnology | $10.42
+3.1% | 1/13/2025 | Target Raised by | Leerink Partners | Analyst Roanna Ruiz | Outperform -> Outperform | $18.00 -> $20.00 | Medium | View details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 1/13/2025 |
MRK Merck & Co., Inc. | $96.18
-1.8% | 1/13/2025 | Target Lowered by | Leerink Partners | Analyst Daina Graybosch | Outperform -> Outperform | $136.00 -> $119.00 | Low | View details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 1/13/2025 |
ACCD Accolade | $6.88
-0.1% | 1/8/2025 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | | N/A | View details for Leerink Partners rating of Accolade (NASDAQ:ACCD) on 1/8/2025 |
DGX Quest Diagnostics | $152.61
+0.9% | 1/6/2025 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $169.00 -> $174.00 | N/A | View details for Leerink Partners rating of Quest Diagnostics (NYSE:DGX) on 1/6/2025 |
ALGN Align Technology | $228.00
+1.7% | 1/6/2025 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $235.00 -> $280.00 | N/A | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 1/6/2025 |
KYMR Kymera Therapeutics | $43.70
+7.6% | 12/27/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $60.00 -> $60.00 | N/A | View details for Leerink Partners rating of Kymera Therapeutics (NASDAQ:KYMR) on 12/27/2024 |
QURE uniQure | $14.91
+6.1% | 12/11/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $26.00 -> $44.00 | N/A | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 12/11/2024 |
|
PDCO Patterson Companies | $30.95
+0.2% | 12/11/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $29.00 -> $31.35 | N/A | View details for Leerink Partners rating of Patterson Companies (NASDAQ:PDCO) on 12/11/2024 |
QTTB Q32 Bio | $3.40
+3.7% | 12/11/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $68.00 -> $9.00 | N/A | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 12/11/2024 |
ANIP ANI Pharmaceuticals | $58.35
-0.2% | 12/11/2024 | Initiated by | Leerink Partners | - | Outperform | $80.00 | N/A | View details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/11/2024 |
MYGN Myriad Genetics | $12.57
+1.5% | 12/9/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $30.00 -> $21.00 | N/A | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 12/9/2024 |
OKUR OnKure Therapeutics | $5.90
+1.9% | 12/5/2024 | Initiated by | Leerink Partners | - | Outperform | $33.00 | N/A | View details for Leerink Partners rating of OnKure Therapeutics (NASDAQ:OKUR) on 12/5/2024 |
RLMD Relmada Therapeutics | $0.37
-0.7% | 12/4/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $10.00 -> $1.00 | N/A | View details for Leerink Partners rating of Relmada Therapeutics (NASDAQ:RLMD) on 12/4/2024 |
RLAY Relay Therapeutics | $4.66
+4.5% | 12/4/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $19.00 -> $18.00 | N/A | View details for Leerink Partners rating of Relay Therapeutics (NASDAQ:RLAY) on 12/4/2024 |
JANX Janux Therapeutics | $40.91
+0.5% | 12/3/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $79.00 -> $91.00 | N/A | View details for Leerink Partners rating of Janux Therapeutics (NASDAQ:JANX) on 12/3/2024 |
CLYM Climb Bio | $1.88
-3.6% | 12/2/2024 | Initiated by | Leerink Partners | - | Outperform | $10.00 | N/A | View details for Leerink Partners rating of Climb Bio (NASDAQ:CLYM) on 12/2/2024 |
ZTS Zoetis | $167.50
+1.0% | 12/2/2024 | Initiated by | Leerink Partners | - | Outperform | $215.00 | N/A | View details for Leerink Partners rating of Zoetis (NYSE:ZTS) on 12/2/2024 |
IDXX IDEXX Laboratories | $427.33
+1.9% | 12/2/2024 | Initiated by | Leerink Partners | - | Outperform | $500.00 | N/A | View details for Leerink Partners rating of IDEXX Laboratories (NASDAQ:IDXX) on 12/2/2024 |
ELAN Elanco Animal Health | $12.04
+0.1% | 12/2/2024 | Initiated by | Leerink Partners | - | Market Perform | $14.00 | N/A | View details for Leerink Partners rating of Elanco Animal Health (NYSE:ELAN) on 12/2/2024 |
AMGN Amgen | $274.81
+1.0% | 11/27/2024 | Target Lowered by | Leerink Partners | - | | $349.00 -> $302.00 | N/A | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 11/27/2024 |
JANX Janux Therapeutics | $40.91
+0.5% | 11/22/2024 | Initiated by | Leerink Partners | - | Outperform | $79.00 | N/A | View details for Leerink Partners rating of Janux Therapeutics (NASDAQ:JANX) on 11/22/2024 |
ABBV AbbVie | $172.41
+0.5% | 11/22/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $206.00 | N/A | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 11/22/2024 |
IQV IQVIA | $205.23
+4.0% | 11/19/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $260.00 -> $248.00 | N/A | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 11/19/2024 |
RCKT Rocket Pharmaceuticals | $10.16
-1.5% | 11/19/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $46.00 -> $44.00 | N/A | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/19/2024 |
EHAB Enhabit | $8.00
+0.1% | 11/19/2024 | Reiterated by | Leerink Partners | - | Market Perform -> Market Perform | $8.50 -> $8.00 | N/A | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 11/19/2024 |
ICLR ICON Public | $205.07
+3.5% | 11/19/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $270.00 -> $255.00 | N/A | View details for Leerink Partners rating of ICON Public (NASDAQ:ICLR) on 11/19/2024 |
ACRS Aclaris Therapeutics | $2.60
+1.2% | 11/19/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $2.00 -> $7.00 | N/A | View details for Leerink Partners rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/19/2024 |
CMPX Compass Therapeutics | $2.61
+0.4% | 11/15/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $5.00 -> $4.00 | N/A | View details for Leerink Partners rating of Compass Therapeutics (NASDAQ:CMPX) on 11/15/2024 |
LXEO Lexeo Therapeutics | $4.88
-3.7% | 11/13/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $20.00 -> $19.00 | N/A | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/13/2024 |
MASS 908 Devices | $3.03
+1.7% | 11/13/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $12.00 -> $4.00 | N/A | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 11/13/2024 |
ARDT Ardent Health Partners | $14.19
+0.6% | 11/12/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $23.00 -> $25.00 | N/A | View details for Leerink Partners rating of Ardent Health Partners (NYSE:ARDT) on 11/12/2024 |
NGNE Neurogene | $16.62
+0.1% | 11/12/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $45.00 -> $72.00 | N/A | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 11/12/2024 |
BMY Bristol-Myers Squibb | $57.01
+1.3% | 11/12/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $55.00 -> $73.00 | N/A | View details for Leerink Partners rating of Bristol-Myers Squibb (NYSE:BMY) on 11/12/2024 |
TECX Tectonic Therapeutic | $41.38
+1.2% | 11/11/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $49.00 -> $69.00 | N/A | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 11/11/2024 |
XRAY DENTSPLY SIRONA | $18.96
+1.0% | 11/7/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | N/A | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 11/7/2024 |
ZYME Zymeworks | $14.29
+3.0% | 11/7/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $10.00 -> $25.00 | N/A | View details for Leerink Partners rating of Zymeworks (NYSE:ZYME) on 11/7/2024 |
BEAM Beam Therapeutics | $24.53
+4.7% | 11/6/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $27.00 -> $39.00 | N/A | View details for Leerink Partners rating of Beam Therapeutics (NASDAQ:BEAM) on 11/6/2024 |
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad) Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. |
IDYA IDEAYA Biosciences | $23.15
+4.4% | 11/5/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $41.00 -> $27.00 | Low | View details for Leerink Partners rating of IDEAYA Biosciences (NASDAQ:IDYA) on 11/5/2024 |
ZURA Zura Bio | $1.79
+1.1% | 11/4/2024 | Initiated by | Leerink Partners | - | Outperform | $15.00 | High | View details for Leerink Partners rating of Zura Bio (NASDAQ:ZURA) on 11/4/2024 |
NVST Envista | $20.53
+3.5% | 10/31/2024 | Upgraded by | Leerink Partners | - | Underperform -> Market Perform | $16.00 -> $23.00 | High | View details for Leerink Partners rating of Envista (NYSE:NVST) on 10/31/2024 |
AQST Aquestive Therapeutics | $3.21
+3.5% | 10/25/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $12.00 -> $13.00 | Low | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 10/25/2024 |
DXCM DexCom | $86.32
+2.3% | 10/25/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $90.00 -> $87.00 | High | View details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/25/2024 |
ICLR ICON Public | $205.07
+3.5% | 10/25/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $376.00 -> $270.00 | High | View details for Leerink Partners rating of ICON Public (NASDAQ:ICLR) on 10/25/2024 |
TENX Tenax Therapeutics | $6.38
+0.2% | 10/24/2024 | Initiated by | Leerink Partners | - | Outperform | $16.00 | High | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 10/24/2024 |
GILD Gilead Sciences | $92.96
+1.2% | 10/21/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $74.00 -> $96.00 | Low | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 10/21/2024 |
TNYA Tenaya Therapeutics | $1.30
-7.1% | 10/18/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | | Low | View details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 10/18/2024 |
AMLX Amylyx Pharmaceuticals | $3.45
-4.2% | 10/18/2024 | Target Set by | Leerink Partners | Analyst Marc Goodman | Market Perform -> Market Perform | $4.00 | High | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 10/18/2024 |
LXRX Lexicon Pharmaceuticals | $0.79
+14.2% | 10/18/2024 | Target Set by | Leerink Partners | Analyst Roanna Ruiz | Outperform -> Outperform | $6.00 | Low | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 10/18/2024 |
ISRG Intuitive Surgical | $604.12
+1.9% | 10/17/2024 | Target Raised by | Leerink Partners | - | | $489.00 -> $502.00 | Low | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/17/2024 |
BBIO BridgeBio Pharma | $36.08
+6.8% | 10/17/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $47.00 -> $46.00 | Low | View details for Leerink Partners rating of BridgeBio Pharma (NASDAQ:BBIO) on 10/17/2024 |
MIRM Mirum Pharmaceuticals | $47.98
+2.2% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $47.00 -> $49.00 | Low | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 10/17/2024 |
ILMN Illumina | $141.31
+3.4% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $160.00 -> $200.00 | Low | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 10/17/2024 |
MASS 908 Devices | $3.03
+1.7% | 10/17/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $15.00 -> $12.00 | Medium | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 10/17/2024 |
NTRA Natera | $167.46
+5.7% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $140.00 -> $150.00 | Medium | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 10/17/2024 |
RVTY Revvity | $123.97
+4.7% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $130.00 -> $135.00 | Low | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 10/17/2024 |
TWST Twist Bioscience | $50.45
+6.1% | 10/17/2024 | Target Raised by | Leerink Partners | - | Market Perform -> Market Perform | $45.00 -> $48.00 | Medium | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 10/17/2024 |
VCYT Veracyte | $43.60
+7.4% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $35.00 -> $40.00 | Low | View details for Leerink Partners rating of Veracyte (NASDAQ:VCYT) on 10/17/2024 |
GH Guardant Health | $45.13
+23.1% | 10/17/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $60.00 -> $50.00 | High | View details for Leerink Partners rating of Guardant Health (NASDAQ:GH) on 10/17/2024 |
WVE Wave Life Sciences | $11.10
+1.0% | 10/16/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $20.00 -> $22.00 | High | View details for Leerink Partners rating of Wave Life Sciences (NASDAQ:WVE) on 10/16/2024 |
VYGR Voyager Therapeutics | $5.22
+3.0% | 10/16/2024 | Initiated by | Leerink Partners | - | Outperform | $15.00 | High | View details for Leerink Partners rating of Voyager Therapeutics (NASDAQ:VYGR) on 10/16/2024 |
MNMD Mind Medicine (MindMed) | $7.18
+0.3% | 10/14/2024 | Initiated by | Leerink Partners | - | Outperform | $20.00 | High | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 10/14/2024 |
STOK Stoke Therapeutics | $9.80
+4.7% | 10/14/2024 | Initiated by | Leerink Partners | - | Outperform | $18.00 | High | View details for Leerink Partners rating of Stoke Therapeutics (NASDAQ:STOK) on 10/14/2024 |
HOLX Hologic | $70.37
+0.9% | 10/8/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $95.00 -> $90.00 | Low | View details for Leerink Partners rating of Hologic (NASDAQ:HOLX) on 10/8/2024 |
TVTX Travere Therapeutics | $19.46
+5.9% | 10/8/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $20.00 -> $20.00 | Medium | View details for Leerink Partners rating of Travere Therapeutics (NASDAQ:TVTX) on 10/8/2024 |
COR Cencora | $245.21
+1.3% | 10/7/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $277.00 -> $275.00 | Low | View details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2024 |
MCK McKesson | $585.51
-1.2% | 10/7/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $665.00 -> $630.00 | Low | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2024 |
HUM Humana | $284.74
+0.7% | 10/2/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $400.00 -> $250.00 | High | View details for Leerink Partners rating of Humana (NYSE:HUM) on 10/2/2024 |
AQST Aquestive Therapeutics | $3.21
+3.5% | 9/30/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $10.00 -> $12.00 | High | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 9/30/2024 |
AGIO Agios Pharmaceuticals | $33.23
+2.5% | 9/27/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $60.00 -> $56.00 | High | View details for Leerink Partners rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 9/27/2024 |
REGN Regeneron Pharmaceuticals | $687.80
+0.9% | 9/24/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $1,175.00 -> $1,077.00 | High | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 9/24/2024 |
BHVN Biohaven | $39.09
+4.0% | 9/23/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $55.00 -> $60.00 | Low | View details for Leerink Partners rating of Biohaven (NYSE:BHVN) on 9/23/2024 |
SPRY ARS Pharmaceuticals | $13.48
+7.2% | 9/20/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $21.00 -> $25.00 | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/20/2024 |
APLT Applied Therapeutics | $0.66
+0.3% | 9/19/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $11.00 -> $14.00 | Low | View details for Leerink Partners rating of Applied Therapeutics (NASDAQ:APLT) on 9/19/2024 |
FDMT 4D Molecular Therapeutics | $4.67
+2.0% | 9/19/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $40.00 -> $36.00 | High | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 9/19/2024 |
PGNY Progyny | $21.48
+2.3% | 9/19/2024 | Target Lowered by | Leerink Partners | - | Market Perform -> Market Perform | $25.00 -> $21.00 | High | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 9/19/2024 |
ICLR ICON Public | $205.07
+3.5% | 9/18/2024 | Initiated by | Leerink Partners | - | Outperform | $379.00 | High | View details for Leerink Partners rating of ICON Public (NASDAQ:ICLR) on 9/18/2024 |
MRNA Moderna | $35.89
+5.4% | 9/17/2024 | Target Lowered by | Leerink Partners | - | Underperform -> Underperform | $60.00 -> $48.00 | Medium | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 9/17/2024 |
ORKA Oruka Therapeutics | $12.98
+6.0% | 9/17/2024 | Initiated by | Leerink Partners | - | Outperform | $44.00 | Low | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/17/2024 |
FULC Fulcrum Therapeutics | $4.00
+1.0% | 9/12/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $4.00 | N/A | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 9/12/2024 |
INSP Inspire Medical Systems | $184.98
+4.1% | 9/10/2024 | Target Raised by | Leerink Partners | - | Market Perform -> Market Perform | $167.00 -> $197.00 | Low | View details for Leerink Partners rating of Inspire Medical Systems (NYSE:INSP) on 9/10/2024 |
MNKD MannKind | $6.04
+0.5% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $7.00 -> $8.00 | Medium | View details for Leerink Partners rating of MannKind (NASDAQ:MNKD) on 9/9/2024 |
PLRX Pliant Therapeutics | $11.07
-1.2% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $46.00 -> $33.00 | Low | View details for Leerink Partners rating of Pliant Therapeutics (NASDAQ:PLRX) on 9/9/2024 |
PRTC PureTech Health | $17.70
+1.1% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $58.00 -> $45.00 | High | View details for Leerink Partners rating of PureTech Health (NASDAQ:PRTC) on 9/9/2024 |
TRVI Trevi Therapeutics | $3.56
-5.3% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $6.00 -> $7.00 | High | View details for Leerink Partners rating of Trevi Therapeutics (NASDAQ:TRVI) on 9/9/2024 |
IMUX Immunic | $0.95
-0.3% | 9/9/2024 | Reiterated by | Leerink Partners | - | Outperform | $5.00 | Low | View details for Leerink Partners rating of Immunic (NASDAQ:IMUX) on 9/9/2024 |
KYMR Kymera Therapeutics | $43.70
+7.6% | 9/9/2024 | Reiterated by | Leerink Partners | - | Outperform | $60.00 | Medium | View details for Leerink Partners rating of Kymera Therapeutics (NASDAQ:KYMR) on 9/9/2024 |
IRWD Ironwood Pharmaceuticals | $3.79
+3.6% | 9/9/2024 | Initiated by | Leerink Partners | - | Market Perform | $5.00 | High | View details for Leerink Partners rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 9/9/2024 |
“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad) Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late. |
GLPG Galapagos | $23.83
+0.3% | 9/9/2024 | Initiated by | Leerink Partners | - | Market Perform | $24.00 | High | View details for Leerink Partners rating of Galapagos (NASDAQ:GLPG) on 9/9/2024 |
GERN Geron | $2.96
+2.4% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $7.00 | Medium | View details for Leerink Partners rating of Geron (NASDAQ:GERN) on 9/9/2024 |
MCK McKesson | $585.51
-1.2% | 9/5/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $670.00 -> $665.00 | Low | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 9/5/2024 |
PCVX Vaxcyte | $88.17
+3.4% | 9/3/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $106.00 -> $153.00 | Low | View details for Leerink Partners rating of Vaxcyte (NASDAQ:PCVX) on 9/3/2024 |
RXRX Recursion Pharmaceuticals | $6.88
+5.4% | 9/3/2024 | Target Lowered by | Leerink Partners | - | Market Perform -> Market Perform | $9.00 -> $8.00 | Low | View details for Leerink Partners rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 9/3/2024 |
NARI Inari Medical | $79.50
-0.1% | 9/3/2024 | Initiated by | Leerink Partners | - | Market Perform | $47.00 | Low | View details for Leerink Partners rating of Inari Medical (NASDAQ:NARI) on 9/3/2024 |
PEN Penumbra | $268.45
+1.8% | 9/3/2024 | Initiated by | Leerink Partners | - | Outperform | $263.00 | Low | View details for Leerink Partners rating of Penumbra (NYSE:PEN) on 9/3/2024 |
TXG 10x Genomics | $16.16
+7.2% | 9/3/2024 | Initiated by | Leerink Partners | - | Outperform | $35.00 | Low | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/3/2024 |
SPRY ARS Pharmaceuticals | $13.48
+7.2% | 8/12/2024 | Target Raised by | Leerink Partners | - | Outperform | $19.00 -> $20.00 | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 8/12/2024 |
ARDT Ardent Health Partners | $14.19
+0.6% | 8/12/2024 | Initiated by | Leerink Partners | - | Outperform | $23.00 | Low | View details for Leerink Partners rating of Ardent Health Partners (NYSE:ARDT) on 8/12/2024 |
ARCT Arcturus Therapeutics | $16.41
-2.3% | 8/12/2024 | Initiated by | Leerink Partners | - | Outperform | $70.00 | Low | View details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/12/2024 |
PGNY Progyny | $21.48
+2.3% | 8/7/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $31.00 -> $25.00 | Low | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 8/7/2024 |
TBPH Theravance Biopharma | $9.15
+6.6% | 8/6/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $15.00 -> $10.00 | Low | View details for Leerink Partners rating of Theravance Biopharma (NASDAQ:TBPH) on 8/6/2024 |
WAT Waters | $413.63
+2.4% | 8/1/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $325.00 -> $375.00 | Low | View details for Leerink Partners rating of Waters (NYSE:WAT) on 8/1/2024 |
TECX Tectonic Therapeutic | $41.38
+1.2% | 7/24/2024 | Initiated by | Leerink Partners | - | Outperform | $49.00 | Low | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 7/24/2024 |
DHR Danaher | $244.18
+2.4% | 7/24/2024 | Target Raised by | Leerink Partners | - | Outperform | $275.00 -> $280.00 | Low | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 7/24/2024 |
HCA HCA Healthcare | $318.47
+2.6% | 7/24/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $367.00 -> $396.00 | Low | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 7/24/2024 |
IONS Ionis Pharmaceuticals | $32.68
+4.0% | 7/24/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $53.00 -> $62.00 | Low | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 7/24/2024 |
ALMS Alumis | $7.41
-3.3% | 7/23/2024 | Initiated by | Leerink Partners | - | Outperform | $29.00 | Low | View details for Leerink Partners rating of Alumis (NASDAQ:ALMS) on 7/23/2024 |
CELC Celcuity | $11.21
+2.6% | 7/22/2024 | Initiated by | Leerink Partners | - | Outperform | $29.00 | Low | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 7/22/2024 |
BNTC Benitec Biopharma | $10.77
+4.6% | 7/22/2024 | Initiated by | Leerink Partners | - | Outperform | $13.00 | Low | View details for Leerink Partners rating of Benitec Biopharma (NASDAQ:BNTC) on 7/22/2024 |
LNTH Lantheus | $94.05
+2.8% | 7/11/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $106.00 -> $127.00 | Low | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 7/11/2024 |
EHC Encompass Health | $95.78
+1.1% | 7/10/2024 | Initiated by | Leerink Partners | - | Outperform | $100.00 | Low | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 7/10/2024 |
HLVX HilleVax | $1.90
| 7/9/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $28.00 -> $2.00 | Low | View details for Leerink Partners rating of HilleVax (NASDAQ:HLVX) on 7/9/2024 |
RVTY Revvity | $123.97
+4.7% | 7/8/2024 | Initiated by | Leerink Partners | - | Outperform | $125.00 | Low | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 7/8/2024 |
SDGR Schrödinger | $21.33
+12.3% | 7/2/2024 | Initiated by | Leerink Partners | - | Outperform | $29.00 | Low | View details for Leerink Partners rating of Schrödinger (NASDAQ:SDGR) on 7/2/2024 |
COR Cencora | $245.21
+1.3% | 6/27/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $275.00 -> $275.00 | Low | View details for Leerink Partners rating of Cencora (NYSE:COR) on 6/27/2024 |
ALNY Alnylam Pharmaceuticals | $264.99
+7.6% | 6/25/2024 | Target Raised by | Leerink Partners | - | Market Perform -> Market Perform | $138.00 -> $159.00 | Low | View details for Leerink Partners rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 6/25/2024 |
SLDB Solid Biosciences | $3.26
-0.3% | 6/24/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $12.00 -> $12.00 | Low | View details for Leerink Partners rating of Solid Biosciences (NASDAQ:SLDB) on 6/24/2024 |
SRPT Sarepta Therapeutics | $116.79
-1.0% | 6/24/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $165.00 -> $230.00 | Low | View details for Leerink Partners rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/24/2024 |
MREO Mereo BioPharma Group | $2.99
+4.5% | 6/20/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $6.00 -> $8.00 | Low | View details for Leerink Partners rating of Mereo BioPharma Group (NASDAQ:MREO) on 6/20/2024 |
QTTB Q32 Bio | $3.40
+3.7% | 5/21/2024 | Initiated by | Leerink Partners | - | Outperform | $54.00 | Low | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $0.53
+3.2% | 5/15/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $3.00 -> $1.00 | Low | View details for Leerink Partners rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/15/2024 |
AIRS AirSculpt Technologies | $5.29
-0.8% | 5/14/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $8.25 -> $5.00 | Low | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
EHAB Enhabit | $8.00
+0.1% | 5/14/2024 | Upgraded by | Leerink Partners | - | Underperform -> Market Perform | $8.50 | Low | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AQST Aquestive Therapeutics | $3.21
+3.5% | 5/10/2024 | Initiated by | Leerink Partners | - | Outperform | $8.00 | Low | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $12.57
+1.5% | 5/8/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $25.00 -> $35.00 | Low | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
BPMC Blueprint Medicines | $111.96
+1.7% | 5/6/2024 | Upgraded by | Leerink Partners | - | Underperform -> Market Perform | $50.00 -> $97.00 | Low | View details for Leerink Partners rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $53.14
+1.0% | 5/1/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $87.00 -> $60.00 | Low | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 5/1/2024 |
LXRX Lexicon Pharmaceuticals | $0.79
+14.2% | 4/30/2024 | Initiated by | Leerink Partners | - | Outperform | $5.00 | Low | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
XOMA XOMA | $26.98
+0.8% | 4/29/2024 | Initiated by | Leerink Partners | - | Outperform | $40.00 | Low | View details for Leerink Partners rating of XOMA (NASDAQ:XOMA) on 4/29/2024 |
NGNE Neurogene | $16.62
+0.1% | 4/29/2024 | Initiated by | Leerink Partners | - | Outperform | $46.00 | Low | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
IMCR Immunocore | $30.00
+3.4% | 4/29/2024 | Initiated by | Leerink Partners | - | Outperform | $74.00 | Low | View details for Leerink Partners rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
CVAC CureVac | $4.14
+1.0% | 4/25/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $12.00 -> $4.00 | Low | View details for Leerink Partners rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
TNDM Tandem Diabetes Care | $35.30
+0.4% | 4/25/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $34.00 -> $45.00 | Low | View details for Leerink Partners rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
RNAC Cartesian Therapeutics | $19.85
+2.9% | 4/23/2024 | Initiated by | Leerink Partners | - | Outperform | $39.00 | Low | View details for Leerink Partners rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $16.88
+6.5% | 4/16/2024 | Initiated by | Leerink Partners | - | Outperform | $47.00 | Low | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $7.18
+0.3% | 4/15/2024 | Initiated by | Leerink Partners | - | Outperform | $20.00 | Low | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $23.82
+5.9% | 4/15/2024 | Initiated by | Leerink Partners | - | Outperform | $32.00 | Low | View details for Leerink Partners rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ARDX Ardelyx | $4.91
-2.0% | 4/5/2024 | Initiated by | Leerink Partners | - | Outperform | $14.00 | Low | View details for Leerink Partners rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad) Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late. |
LRMR Larimar Therapeutics | $3.43
+2.7% | 4/3/2024 | Initiated by | Leerink Partners | - | Outperform | $25.00 | Low | View details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $78.28
+3.2% | 4/1/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $69.00 -> $110.00 | Low | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $4.13
-5.9% | 3/25/2024 | Initiated by | Leerink Partners | - | Outperform | $26.00 | Low | View details for Leerink Partners rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
WBA Walgreens Boots Alliance | $11.37
-9.2% | 3/18/2024 | Target Lowered by | Leerink Partners | - | Market Perform -> Market Perform | $23.00 -> $22.00 | Low | View details for Leerink Partners rating of Walgreens Boots Alliance (NASDAQ:WBA) on 3/18/2024 |
MIRM Mirum Pharmaceuticals | $47.98
+2.2% | 3/18/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $44.00 -> $43.00 | Low | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 3/18/2024 |
RGLS Regulus Therapeutics | $1.26
+1.6% | 3/18/2024 | Initiated by | Leerink Partners | - | Outperform | $6.00 | Low | View details for Leerink Partners rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.37
+2.5% | 3/14/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $9.00 -> $2.00 | Low | View details for Leerink Partners rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $3.45
-4.2% | 3/11/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $7.57
+2.7% | 3/6/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $37.00 | Low | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $13.48
+7.2% | 3/5/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $6.00 -> $18.00 | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $3.34
+0.3% | 3/4/2024 | Initiated by | Leerink Partners | - | Outperform | $48.00 | Low | View details for Leerink Partners rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
WBA Walgreens Boots Alliance | $11.37
-9.2% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $23.00 | Low | View details for Leerink Partners rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $18.96
+1.0% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $42.00 | Low | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
PGNY Progyny | $21.48
+2.3% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $49.00 | Low | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
PINC Premier | $22.09
-1.5% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $22.50 | Low | View details for Leerink Partners rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $30.95
+0.2% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $36.00 | Low | View details for Leerink Partners rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $14.93
+2.4% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $24.00 | Low | View details for Leerink Partners rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $585.51
-1.2% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $600.00 | Low | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 2/26/2024 |
LH Laboratory Co. of America | $244.39
+2.4% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $260.00 | Low | View details for Leerink Partners rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
IQV IQVIA | $205.23
+4.0% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $290.00 | Low | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HIMS Hims & Hers Health | $29.71
+6.7% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $10.00 | Low | View details for Leerink Partners rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $4.71
+3.1% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $8.00 | Low | View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
NVST Envista | $20.53
+3.5% | 2/26/2024 | Initiated by | Leerink Partners | - | Underperform | $19.00 | Low | View details for Leerink Partners rating of Envista (NYSE:NVST) on 2/26/2024 |
TDOC Teladoc Health | $9.50
+4.5% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $17.00 | Low | View details for Leerink Partners rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
CVS CVS Health | $53.14
+1.0% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $88.00 | Low | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 2/26/2024 |
HSIC Henry Schein | $74.19
+1.3% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $78.00 | Low | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
DGX Quest Diagnostics | $152.61
+0.9% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $135.00 | Low | View details for Leerink Partners rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
DOCS Doximity | $55.52
+3.3% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $32.00 | Low | View details for Leerink Partners rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $12.61
+8.1% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $19.00 | Low | View details for Leerink Partners rating of Certara (NASDAQ:CERT) on 2/26/2024 |
COR Cencora | $245.21
+1.3% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $261.00 | Low | View details for Leerink Partners rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $127.81
+1.2% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $125.00 | Low | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
ALGN Align Technology | $228.00
+1.7% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $310.00 | Low | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $6.88
-0.1% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $16.00 | Low | View details for Leerink Partners rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
APLT Applied Therapeutics | $0.66
+0.3% | 2/22/2024 | Initiated by | Leerink Partners | - | Outperform | $12.00 | Low | View details for Leerink Partners rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $1.20
| 2/21/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $42.00 -> $10.00 | Low | View details for Leerink Partners rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
BTSG BrightSpring Health Services | $20.89
+12.6% | 2/20/2024 | Initiated by | Leerink Partners | - | Outperform | $15.00 | Low | View details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
ENGN enGene | $6.97
-2.4% | 2/20/2024 | Initiated by | Leerink Partners | - | Outperform | $31.00 | Low | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
SYBX Synlogic | $1.43
-2.1% | 2/9/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $274.81
+1.0% | 2/7/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $324.00 -> $318.00 | Low | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $367.97
+2.5% | 2/5/2024 | Initiated by | Leerink Partners | - | Outperform | $330.00 | Low | View details for Leerink Partners rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $2.45
-6.1% | 1/31/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $5.00 -> $18.00 | Low | View details for Leerink Partners rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $13.06
+9.1% | 1/30/2024 | Initiated by | Leerink Partners | - | Outperform | $22.00 | Low | View details for Leerink Partners rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $10.17
+1.8% | 1/29/2024 | Initiated by | Leerink Partners | - | Outperform | $30.00 | Low | View details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $1.53
+2.0% | 1/23/2024 | Initiated by | Leerink Partners | - | Outperform | $12.00 | Low | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AGL agilon health | $3.42
+10.5% | 1/8/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of agilon health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $9.38
+1.1% | 12/22/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $11.10
+1.0% | 12/19/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $5.00 -> $12.00 | Low | View details for Leerink Partners rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
INCY Incyte | $73.47
+2.1% | 12/13/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $78.00 | Low | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 12/13/2023 |
NBTX Nanobiotix | $3.25
+7.3% | 12/8/2023 | Initiated by | Leerink Partners | - | Outperform | $11.00 | Low | View details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TNYA Tenaya Therapeutics | $1.30
-7.1% | 11/30/2023 | Initiated by | Leerink Partners | - | Outperform | $7.00 | Low | View details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad) Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late. |
LXEO Lexeo Therapeutics | $4.88
-3.7% | 11/28/2023 | Initiated by | Leerink Partners | - | Outperform | $19.00 | Low | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $6.37
+3.4% | 11/14/2023 | Initiated by | Leerink Partners | - | Outperform | $20.00 | Low | View details for Leerink Partners rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
ZNTL Zentalis Pharmaceuticals | $2.25
+0.4% | 11/7/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $15.00 | Low | View details for Leerink Partners rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $2.45
-6.1% | 10/30/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $6.00 | Low | View details for Leerink Partners rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $24.53
+4.7% | 10/20/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $75.00 -> $20.00 | Low | View details for Leerink Partners rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $4.67
+2.0% | 10/18/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $24.00 | Low | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
AXGN AxoGen | $18.97
+4.9% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $9.00 | Low | View details for Leerink Partners rating of AxoGen (NASDAQ:AXGN) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $69.75
-8.2% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $37.00 | Low | View details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
DXCM DexCom | $86.32
+2.3% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $110.00 | Low | View details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
EW Edwards Lifesciences | $69.94
+0.2% | 10/16/2023 | Initiated by | Leerink Partners | - | Market Perform | $75.00 | Low | View details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
INSP Inspire Medical Systems | $184.98
+4.1% | 10/16/2023 | Initiated by | Leerink Partners | - | Market Perform | $159.00 | Low | View details for Leerink Partners rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
TNDM Tandem Diabetes Care | $35.30
+0.4% | 10/16/2023 | Initiated by | Leerink Partners | - | Market Perform | $21.00 | Low | View details for Leerink Partners rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
ISRG Intuitive Surgical | $604.12
+1.9% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $342.00 | Low | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/16/2023 |
VCEL Vericel | $59.56
+0.8% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $42.00 | Low | View details for Leerink Partners rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
PODD Insulet | $276.08
+0.1% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $184.00 | Low | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
AMGN Amgen | $274.81
+1.0% | 10/11/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $267.00 -> $318.00 | Low | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
NBIX Neurocrine Biosciences | $145.88
+1.8% | 10/6/2023 | Target Raised by | Leerink Partners | Analyst M. Goodman | | $125.00 -> $135.00 | Low | View details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 10/6/2023 |
GPCR Structure Therapeutics | $28.34
+4.7% | 9/29/2023 | Target Raised by | Leerink Partners | - | | $46.00 -> $97.00 | Low | View details for Leerink Partners rating of Structure Therapeutics (NASDAQ:GPCR) on 9/29/2023 |
SPRY ARS Pharmaceuticals | $13.48
+7.2% | 9/21/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
PTCT PTC Therapeutics | $45.25
+3.2% | 9/18/2023 | Target Lowered by | Leerink Partners | Analyst J. Schwartz | | $44.00 -> $30.00 | Low | View details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 9/18/2023 |
SPRB Spruce Biosciences | $0.37
+2.5% | 9/8/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $3.00 -> $9.00 | Low | View details for Leerink Partners rating of Spruce Biosciences (NASDAQ:SPRB) on 9/8/2023 |
DSGN Design Therapeutics | $4.87
-3.8% | 8/15/2023 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $6.00 | Low | View details for Leerink Partners rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $45.82
+0.2% | 8/15/2023 | Initiated by | Leerink Partners | - | Outperform | $58.00 | Low | View details for Leerink Partners rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
EXEL Exelixis | $36.43
+0.6% | 8/8/2023 | Initiated by | Leerink Partners | - | Market Perform | $18.00 | Low | View details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $23.15
+4.4% | 8/8/2023 | Initiated by | Leerink Partners | - | Outperform | $33.00 | Low | View details for Leerink Partners rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
NUVL Nuvalent | $78.28
+3.2% | 8/8/2023 | Initiated by | Leerink Partners | - | Market Perform | $42.00 | Low | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
NVCR NovoCure | $26.96
+3.0% | 8/4/2023 | Initiated by | Leerink Partners | - | Outperform | $51.00 | Low | View details for Leerink Partners rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $58.22
+3.6% | 7/26/2023 | Reiterated by | Leerink Partners | Analyst M. Goodman | Outperform | $25.00 | Low | View details for Leerink Partners rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
NBIX Neurocrine Biosciences | $145.88
+1.8% | 7/24/2023 | Upgraded by | Leerink Partners | Analyst M. Goodman | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX Cryoport | $8.16
+8.8% | 7/13/2023 | Downgraded by | Leerink Partners | Analyst P. Souda | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Cryoport (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol-Myers Squibb | $57.01
+1.3% | 7/10/2023 | Reiterated by | Leerink Partners | Analyst D. Risinger | Market Perform | | Low | View details for Leerink Partners rating of Bristol-Myers Squibb (NYSE:BMY) on 7/10/2023 |
EHAB Enhabit | $8.00
+0.1% | 6/20/2023 | Reiterated by | Leerink Partners | Analyst W. Mayo | Underperform | | Low | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 6/20/2023 |
OCS Oculis | $22.64
-0.4% | 6/12/2023 | Reiterated by | Leerink Partners | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partners rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
BPMC Blueprint Medicines | $111.96
+1.7% | 6/5/2023 | Downgraded by | Leerink Partners | Analyst A. Berens | Market Perform -> Underperform | | Low | View details for Leerink Partners rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023 |
ELEV Elevation Oncology | $0.71
+0.0% | 5/30/2023 | Upgraded by | Leerink Partners | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023 |
BOLT Bolt Biotherapeutics | $0.53
+3.2% | 5/12/2023 | Upgraded by | Leerink Partners | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/12/2023 |
ARWR Arrowhead Pharmaceuticals | $19.76
+1.0% | 5/12/2023 | Downgraded by | Leerink Partners | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
DHR Danaher | $244.18
+2.4% | 5/1/2023 | Reiterated by | Leerink Partners | Analyst P. Souda | Outperform | | Low | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 5/1/2023 |
PRTA Prothena | $14.11
+2.5% | 4/24/2023 | Reiterated by | Leerink Partners | Analyst R. Li | Outperform | | Low | View details for Leerink Partners rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
GNFT Genfit | $3.66
+5.5% | 4/14/2023 | Reiterated by | Leerink Partners | Analyst T. Smith | Outperform | | Low | View details for Leerink Partners rating of Genfit (NASDAQ:GNFT) on 4/14/2023 |
CNTB Connect Biopharma | $1.08
+2.9% | 4/12/2023 | Reiterated by | Leerink Partners | Analyst T. Smith | Outperform | | Low | View details for Leerink Partners rating of Connect Biopharma (NASDAQ:CNTB) on 4/12/2023 |
ARWR Arrowhead Pharmaceuticals | $19.76
+1.0% | 4/12/2023 | Upgraded by | Leerink Partners | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $61.11
+10.5% | 4/11/2023 | Reiterated by | Leerink Partners | Analyst R. Ruiz | Market Perform | $25.00 | Low | View details for Leerink Partners rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
ACLX Arcellx | $66.57
+0.1% | 3/30/2023 | Target Raised by | Leerink Partners | - | Outperform | $35.00 -> $39.00 | Low | View details for Leerink Partners rating of Arcellx (NASDAQ:ACLX) on 3/30/2023 |
ABT Abbott Laboratories | $116.78
+2.9% | 3/31/2023 | Target Raised by | Leerink Partners | - | Market Perform | $90.00 -> $102.00 | Low | View details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 3/31/2023 |
REGN Regeneron Pharmaceuticals | $687.80
+0.9% | 3/27/2023 | Upgraded by | Leerink Partners | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
PTCT PTC Therapeutics | $45.25
+3.2% | 3/17/2023 | Reiterated by | Leerink Partners | Analyst J. Schwartz | Market Perform | $48.00 | Low | View details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
CNTA Centessa Pharmaceuticals | $16.46
+8.6% | 3/17/2023 | Reiterated by | Leerink Partners | Analyst D. Risinger | Outperform | $6.00 | Low | View details for Leerink Partners rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
HALO Halozyme Therapeutics | $55.94
+2.1% | 3/16/2023 | Downgraded by | Leerink Partners | Analyst D. Risinger | Outperform -> Market Perform | $42.00 | Low | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
ARGX argenx | $647.39
+1.1% | 3/3/2023 | Target Raised by | Leerink Partners | - | Outperform | $430.00 -> $435.00 | Low | View details for Leerink Partners rating of argenx (NASDAQ:ARGX) on 3/3/2023 |
GPCR Structure Therapeutics | $28.34
+4.7% | 2/28/2023 | Reiterated by | Leerink Partners | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partners rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
CGEN Compugen | $2.27
+0.9% | 2/28/2023 | Reiterated by | Leerink Partners | Analyst D. Graybosch | Outperform | | Low | View details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 2/28/2023 |
IRON Disc Medicine | $60.52
+3.9% | 2/28/2023 | Reiterated by | Leerink Partners | Analyst T. Smith | Outperform | $36.00 | Low | View details for Leerink Partners rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
XNCR Xencor | $20.45
+6.3% | 2/23/2023 | Reiterated by | Leerink Partners | Analyst J. Chang | Outperform | | Low | View details for Leerink Partners rating of Xencor (NASDAQ:XNCR) on 2/23/2023 |
MRNA Moderna | $35.89
+5.4% | 2/24/2023 | Downgraded by | Leerink Partners | Analyst M. Foroohar | Market Perform -> Underperform | $111.00 -> $93.00 | Low | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
NKTR Nektar Therapeutics | $0.90
+1.3% | 2/24/2023 | Target Lowered by | Leerink Partners | - | Market Perform | $5.00 -> $3.00 | N/A | View details for Leerink Partners rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
BPMC Blueprint Medicines | $111.96
+1.7% | 2/24/2023 | Target Lowered by | Leerink Partners | - | Market Perform | $45.00 -> $38.00 | Low | View details for Leerink Partners rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $32.68
+4.0% | 2/23/2023 | Target Lowered by | Leerink Partners | - | Market Perform | $34.00 -> $27.00 | Low | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $9.50
+4.5% | 2/23/2023 | Upgraded by | Leerink Partners | Analyst S. Davis | Market Perform -> Outperform | $34.00 | Low | View details for Leerink Partners rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $172.41
+0.5% | 2/10/2023 | Upgraded by | Leerink Partners | Analyst D. Risinger | Underperform -> Market Perform | $135.00 -> $153.00 | Low | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
